DOCSLIB.ORG

2020 FOCIS Abstract Supplement Federation of Clinical Immunology Societies October 28-31, 2020 Virtual Annual Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 FOCIS Abstract Supplement Federation of Clinical Immunology Societies October 28-31, 2020 Virtual Annual Meeting 2020 FOCIS Abstract Supplement Federation of Clinical Immunology Societies October 28-31, 2020 Virtual Annual Meeting FOCIS 2020 Abstract Supplement Table of Contents Abstracts by Subject Area 3 Allergy/Asthma 3 Autoimmunity 13 Cell and Gene Therapies 83 COVID-19 100 Genetics and Epigenetics 111 Human B Cells and Antibodies 120 Immune Monitoring 125 Immunodeficiency (primary or acquired) 136 Immunology of the Eye 139 Immunomodulation 142 Immuno-oncology 156 Infectious Diseases 184 Inflammatory Diseases 207 Innate Immunity 228 Leukocyte Migration 234 Metabolism and Microbiome 235 NK Cells and Innate Lymphocytes 239 Stem Cell and Organ Transplantation 242 Systems Immunology 258 2 Allergy/asthma F52. The Impact of Immunosenescence on Immune Responses in Older Individuals after Influenza Vaccination Inna Ovsyannikova, Richard Kennedy, Iana Haralambieva, Diane Grill and Gregory Poland Mayo Clinic, Rochester, MN The goal of this study was to examine associations between age and immunosenescence markers (T- cell receptor excision circle [TREC] frequency, telomerase [TERT] expression, CD28 expression on T- cells, and the CD4+/CD8+T-cell ratio) and vaccine-induced immune responses (HAI/VNA/B-cell Elispot) and identify immunosenescence-associated differences in gene expression (mRNA-Seq) and gene regulation (miRNA-Seq/DNA methylation) in older adults (159 healthy subjects; 50-74 yo; 61.6% female; 98.7% Caucasians) receiving TIV (Fluarix) vaccination. A positive correlation (r=0.49) was observed between the %CD4+CD28- and %CD8+CD28- cells and a negative correlation (r=-0.33) was found between TREC and %CD8+CD28- cells. The peak antibody response (HAI/VNA titer at Day 28) was negatively associated with age (r=-0.2, p=0.04). TERT activity was positively correlated with the memory B-cell response at Day 28 compared to baseline (p=0.025). TREC levels were positively correlated with the baseline and early (Day 3) influenza A/H1N1-specific B-cell response (p=0.04 and 0.035, respectively). We identified an interconnected set of gene expression pathways (antigen processing/presentation/MAPK/mTOR/TCR/BCR/calcium signaling) that were associated with immunosenescence markers, such as TERT, TREC, %CD4+CD28- and %CD8+CD28- cells. We discovered several miRNAs (miR-320a,b,d) associated with chronological age, %CD4+CD28- cells and CD4+/CD8+T-cell ratio (p< 0.003). We found several CpGs (KLF14/TSPAN33) associated with age within the genes controlling immune function. We found that immune cell composition/gene expression/CpG methylation may provide distinct information for the prediction of humoral immune response outcomes. Our data suggest that influenza-specific immunity is significantly influenced by age, and that specific markers of immunosenescence are correlated with different humoral immune response outcomes observed after vaccination in older individuals. F96. A novel role for long noncoding RNAs in airway responses to type 2 cytokines. ADAM WILLIAMS1, Grace Kwon2 and Marina Yurieva1 1The Jackson Laboratory for Genomic Medicine, Farmington, CT, 2The jackson laboratory for genomic medicine, farmington, CT During type 2 inflammation, such as in allergic asthma, IL13 signals through STAT (Signal Transducer and Activator of Transcription) proteins to drive pathophysiological changes in the airway epithelium, including increased mucus production, goblet cell metaplasia, and loss of ciliated cells. How these changes are coordinated is poorly understood. Long non-coding RNAs (lncRNAs) do not encode proteins; rather, some produce functional RNA transcripts that are powerful regulators of cellular identity and function. Using RNA-seq we identified a lncRNA that is induced directly by STAT6 following IL-13 activation. Using CRISPR/Cas9, ATAC-Seq and single-cell RNA-Seq, we have determined that this lncRNA coordinates the response of the airway epithelium to IL13 and hypothesize it provides a 3 mechanistic link between IL13 signaling and lung pathology seen in asthma. The work highlights a new role for lncRNAs as central regulators of airway epithelial cell biology, and as potential therapeutic targets for asthma. F167. An Endothelial MicroRNA-1–regulated Network Controls Eosinophil Trafficking in Asthma and Chronic Rhinosinusitis. shervin (Seyedtaghi) Takyar1, Asawari Korde1, farida Ahangari2, jose gomez1, geoffrey chupp1, Jordan Pober1 and anjelica Gonzalez3 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, New haven, CT, 3Yale School of Engineering and Applied Science, New haven, CT Background: Airway eosinophilia is a prominent feature of asthma and chronic rhinosinusitis, (CRS) and endothelium plays a key role in regulating eosinophil trafficking. MicroRNA-1 (miR-1) is the only miRNA reported to be altered in the endothelium of murine asthma models. Objective: We sought to determine the specific role of endothelial miR-1 in regulating the eosinophilic response. Methods: We measured miRNA and mRNA expression by quantitative RT-PCR. We used ovalbumin and house dust mite models of asthma and overexpressed miR-1 through delivery of a lentiviral vector or induction of an endothelial-specific transgene. Tissue eosinophilia was quantified by Congo red and anti-eosinophil peroxidase staining. We measured eosinophil binding using Sykes-Moore adhesion chamber. Target recruitment to miRNA induced silencing complex (miRISC) was assessed by anti- Argonaute2 RNA immune-precipitation. Surface p-selectin was measured by flow cytometry. Results: Serum miR-1 levels had inverse correlations with sputum eosinophilia, airway obstruction, and number of hospitalizations in asthma patients. MiR-1 also had an inverse correlation with eosinophilia in CRS tissue samples. IL-13 decreased miR-1 levels in human lung endothelium. Endothelial-specific overexpression of miR-1 reduced airway eosinophilia and asthma phenotypes in murine models and inhibited IL-13-induced eosinophil binding to endothelial cells. MiR-1 recruited P-selectin, thymic stromal lymphopoietin, eotaxin-3, and thrombopoietin receptor to the miRISC. Expression of these target genes in our CRS and asthma cohorts correlated inversely with miR-1 levels. Further, miR-1 decreased surface P-selectin levels in the IL-13-stimulated endothelial cells. Conclusion: Endothelial miR-1 regulates eosinophil trafficking in allergic airway inflammation. MiR-1 has therapeutic potential in asthma and CRS. F182. Distinct gut microbiota profiles during active oral immunotherapy of peanut allergic subjects and healthy controls. Ziyuan He1, Wenming Zhang1, Rose Szabady2, Gouri Vadali2, Jason Norman2, Bruce Roberts2, Rebecca Chinthrajah3, Stephen Galli1, Kari Nadeau4 and Sandra Andorf1 4 1Stanford University, Stanford, CA, 2Vedanta Biosciences, Inc., Cambridge, MA, 3Stanford University, School of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, 4Stanford University School of Medicine, Stanford, CA Background: The prevalence of food allergy (FA) is increasing and has been associated with changes in gut microbiota. Oral Immunotherapy (OIT) is a widely studied immunotherapy to FA however the roles of gut microbiota during OIT are poorly understood. In this pilot study, we sought to study the gut microbiome alterations from peanut allergic participants who underwent peanut OIT and compared with heathy controls. Methods: Stool samples were collected from peanut allergic participants at baseline, during OIT, and after a 13-week phase of withdrawal (n=16) or a daily dose of 300 mg (n=10) or from healthy controls (n=39). Shotgun metagenomic sequencing was performed and analyzed for taxonomic classifications. Alpha diversity was calculated and compared by Wilcoxon signed-rank test. Beta diversity was analyzed by Principal Coordinates Analysis (PCoA), then the difference was compared by Permutational Multivariate Analysis of Variance. Results: The PCoA analysis revealed significant and independent separations between peanut allergic participants at baseline and healthy controls (p< 0.001) as well as for the ages of the individuals (p< 0.001). During OIT, significantly increased alpha diversities measured by richness (p< 0.05), Shannon index (p< 0.05), and Pielou’s evenness (p< 0.05) were observed in seven participants at week 52 of OIT compared to baseline. Conclusion: The PCoA analysis suggested different microbial communities in peanut allergic and healthy individuals. During OIT, the significantly increased alpha diversity at week 52 compared to baseline might suggest that actively increasing doses of peanut during OIT induces an increase gut microbial diversity in our pilot study. F258. Characterization of the immune response in autoimmune chronic urticaria patients and the effect of anti-IgE treatment Cristina Alejandra Lopez1, Bibiana Quirant-Sanchez2, Nathalie Depreux3, Armando Ruiz3, Isabel Bielsa3, Eva M Martínez-Caceres3 and Aina Teniente-Serra3 1Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain, 2Germans Trias i Pujol University Hospital and Research Institute. FOCIS Center of Excellence- UAB- Barcelona, Barcelona, Catalonia, Spain, 3Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain Introduction The pathogenic mechanisms involved in chronic urticaria (CU) are complex. In approximately 40% of the patients, an autoimmune pathogenesis IgG mediated is involved and an association with autoimmune thyroid disease was reported. Anti-IgE treatment with omalizumab is used to treat CU patients leading to clinical improvement. The relationship between omalizumab and
Load more

Recommended publications
  • Factors Influencing Clinical Trial Site Selection in Europe
    BMJ Open: first published as 10.1136/bmjopen-2013-002957 on 15 November 2013. Downloaded from Open Access Research Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study) Marta Gehring,1 Rod S Taylor,2 Marie Mellody,3 Brigitte Casteels,4 Angela Piazzi,3 Gianfranco Gensini,5 Giuseppe Ambrosio6 To cite: Gehring M, ABSTRACT et al Strengths and limitations of this study Taylor RS, Mellody M, . Objectives: Applications to run clinical trials in Factors influencing clinical Europe fell 25% between 2007 and 2011. Costs, speed ▪ trial site selection in Europe: We provide systematic evidence across a large of approvals and shortcomings of European Clinical the Survey of Attitudes sample of expert professionals indicating that towards Trial sites in Europe Trial Directive are commonly invoked to explain this fostering competitiveness of European clinical (the SAT-EU Study). BMJ unsatisfactory performance. However, no hard evidence research may not require additional government Open 2013;3:e002957. is available on the actual weight of these factors or has spending/incentives. Carefully crafted harmonisa- doi:10.1136/bmjopen-2013- it been previously investigated whether other criteria tion of approvals, greater visibility of centres of 002957 may also impact clinical trial site selection. excellence via disease networks/the web, and Design: The Survey of Attitudes towards Trial sites in reduction of ‘hidden’ costs are more likely to ▸ Prepublication history for Europe (SAT-EU Study) was an anonymous, cross- boost competitiveness of European clinical this paper is available online. sectional web-based survey that systematically research.
    [Show full text]
  • Industry Roles and Responsibilities
    IBCs in a Changing Research Landscape: A Policy Conference Industry: Roles and Responsibilities Steven A. Kradjian Executive Director, Regulatory Affairs VICAL Incorporated Progress Over 480 gene transfer trials are recorded on the OBA protocol list 86% Phase I studies 13% (64) of these in phase 2 1% (3) of these trials in phase 3. What has changed in the research landscape? Human gene transfer studies moved beyond Phase 1 research to late stage development Phase 2, Phase 3. Better characterized product Industry sponsors ~2/3 of human gene transfer clinical trials. Industry is a major partner in realizing and delivering potential benefits of gene-based medicines. Human Gene Transfer Research: FDA findings of Good Clinical Practices During 2000, FDA inspections 70 clinical study sites Industry and Academic Sponsors GCP compliance acceptable GCP deviations not different from other bioresearch programs Random Sampling of Phase 1 and 2 INDs, FDA March 2000 24 IND Sponsors of 70 Clinical Investigators Human Gene Transfer Participating in these Research INDs Independent 70.8% (17/24) 27.1% (19/70) Government (DHHS) 4.1% (1/24) 7.1% (5/70) Industry 25% (6/24) 65.7% (46/70) Gene Transfer Clinical Investigator Inspections A Comparison FDA inspected 70 randomly selected clinical investigators for GCP compliance. NAI VAI OAI GT 38% 55.9% 5.0% 2000 total 30.9% 57.1% 11.9% 2000w/o GT 21.4% 60% 18.5% 1999 28.5% 54.2% 17.1% 1998 34.9% 53% 12% Random surveillance inspections of Phase 1 and 2 gene therapy clinical trials indicates the trials were being properly conducted with fewer deviations than found in Phase 3 studies.
    [Show full text]
  • UMC Utrecht Research Evaluation
    UMC Utrecht Research Evaluation 2013-2018 Table of contents UMC Utrecht research Self-evaluation report 3 Self-evaluation strategic research program Brain 33 Self-evaluation report strategic research program Cancer 82 Self-evaluation report strategic research program Child Health 150 Self-evaluation report strategic research program Circulatory Health 218 Self-evaluation report strategic research program Infection & Immunity 294 Self-evaluation report strategic research program Regenerative Medicine & Stem Cells 352 UMC Utrecht research Self-evaluation report (2013-2018) Foreword 5 1. Mission, strategy & general organisation 6 1.1 Mission 6 1.2 Strategy 2015-2020 ‘Connecting U’ 6 1.3 Executive Board 6 1.4 Supervisory Board 6 1.5 Organisation 7 1.6 Governance developments 7 1.7 Patient and public involvement 7 1.8 Educational Research 8 2. Research organisation & key figures 9 2.1 Strategic research programs 9 2.2 Management and responsibilities 10 2.3 Research FTE 11 2.4 Professorships 11 2.5 Diversity 11 2.6 Funding and earning capacity 12 2.7 Facilities 14 2.8 Partners and collaborations 14 3. Research policy & support 17 3.1 Research Office 17 3.2 Support for innovation and funding 17 3.3 Compliance and quality management of clinical research 18 3.4 Integrity 18 3.5 Data management 19 3.6 Open Science 19 3.7 Benchmark: Research evaluation practices at the UMC Utrecht 20 4. PhD programs: Graduate School of Life Sciences 22 4.1 Recruitment, selection & admission 22 4.2 PhD enrolment 22 4.3 PhD training 23 4.4 Supervision 24 4.5 Governance 24 5.
    [Show full text]
  • Draft New Drugs and Clinical Trials Rules, 2018
    DRAFT NEW DRUGS AND CLINICAL TRIALS RULES, 2018 SUBMISSIONS TO THE MINISTRY OF HEALTH AND FAMILY WELFARE Dhvani Mehta Nivedita Saksena March, 2018 www.vidhilegalpolicy.in This Report is an independent, non-commissioned piece of academic work. The authors would like to thank Jitin Ahuja for his inputs. The Vidhi Centre for Legal Policy is an independent think-tank doing legal research and assisting government in making better laws. For more information, see www.vidhilegalpolicy.in About the Authors Dhvani Mehta is a Senior Resident Fellow at the Vidhi Centre for Legal Policy working in the Vidhi Aid initiative. Nivedita Saksena is a Research Fellow at the Vidhi Centre for Legal Policy working in the Vidhi Aid initiative. © Vidhi Centre for Legal Policy, 2018 EXECUTIVE SUMMARY 1 EXECUTIVE SUMMARY In a notification dated February 1, 2018, the Central Government invited comments on the draft New Drugs and Clinical Trials Rules, 2018 (“Rules”). These Rules regulate the conduct of clinical trials (including clinical trial related injury and compensation), bioavailability and bioequivalence studies, and the import and manufacture of new drugs. They also govern the functioning of several entities such as the Central Licensing Authority, Ethics Committees and Bioavailability and Bioequivalence Study Centres. These entities and processes are currently governed by scattered provisions contained in the current Drugs and Cosmetics Rules, 1945, several gazette notifications, circulars and office orders. These Rules are a welcome step, and will help to consolidate and streamline the provisions under these different instruments. They will also increase regulatory certainty. However, certain issues must be addressed before these Rules can be effectively implemented.
    [Show full text]
  • Project Final Report
    PROJECT FINAL REPORT Publishable Grant Agreement number: HEALTH-F1-2007-201002 Project acronym: ICREL Project title: IMPACT ON CLINICAL RESEARCH OF EUROPEAN LEGISLATION Funding Scheme: CSA COORDINATION AND SUPPORT ACTION – SA SUPPORTING ACTION Period covered: from 01 January 2008 to 31 December 2008 Project co-ordinator name, Title and Organisation: Dr. Ingrid Klingmann, Project Coordinator, EFGCP Tel: +32 2 784 36 93 Fax: +32 2 784 30 66 E-mail: [email protected] Project website address: www.efgp.be/ICREL 1 ICREL – FINAL REPORT PUBLISHABLE – FEBRUARY 2009 Impact on Clinical Research of European Legislation (ICREL) Final Report – First Version 09 February 2009 European Commission, Directorate Research Grant Agreement Number: HEALTH‐F1‐2007‐201002 Submitted by the European Forum for Good Clinical Practice (EFGCP) in collaboration with European Clinical Research Infrastructures Network (ECRIN) European Organisation for Research and Treatment of Cancer (EORTC) Ethics Committee, Medical University of Vienna Hospital Clinic I Provincial de Barcelona Contact: Dr. Ingrid Klingmann European Forum for Good Clinical Practice Rue de l’Industrie 4 1000 Brussels Belgium Tel: +32 2 732 87 83 E‐mail: [email protected] - 2 - Table of Contents The Consortium....................................................................................................................................7 Executive Summary .............................................................................................................................8 Introduction
    [Show full text]
  • Application of Incident Command Structure to Clinical Trial Management in the Academic Setting: Principles and Lessons Learned Penny S
    Virginia Commonwealth University VCU Scholars Compass Anesthesiology Publications Dept. of Anesthesiology 2017 Application of Incident Command Structure to clinical trial management in the academic setting: principles and lessons learned Penny S. Reynolds Virginia Commonwealth University, [email protected] Mary J. Michael Virginia Commonwealth University Bruce D. Spiess Virginia Commonwealth University Follow this and additional works at: http://scholarscompass.vcu.edu/anesth_pubs Part of the Anesthesiology Commons © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The rC eative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Downloaded from http://scholarscompass.vcu.edu/anesth_pubs/6 This Article is brought to you for free and open access by the Dept. of Anesthesiology at VCU Scholars Compass. It has been accepted for inclusion in Anesthesiology Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Reynolds et al. Trials (2017) 18:62 DOI 10.1186/s13063-016-1755-9 METHODOLOGY Open Access Application of Incident Command Structure to clinical trial management in the academic setting: principles and lessons learned Penny S. Reynolds1,2*, Mary J. Michael1,2 and Bruce D. Spiess1,2 Abstract Background: Clinical trial success depends on appropriate management, but practical guidance to trial organisation and planning is lacking.
    [Show full text]
  • Annual Work Plan 2020 Would Then Be Updated Accordingly
    Ref. Ares(2020)3206340 - 19/06/2020 In accordance with Article 16 of the Statutes of the IMI2 JU annexed to Council Regulation (EU) No 557/2014 of 6 May 2014 and with Article 33 of the Financial Rules of the IMI2 JU. The third amended Annual Work Plan will be made publicly available after its adoption by the Governing Board. Sole annex to the Decision of the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking no. IMI2-GB-DEC-2020-20 adopted on 19.06.2020 Page 1 of 238 Table of Contents 1 Introduction ................................................................................................................................................... 5 2 Annual Work Plan Year 2020 ....................................................................................................................... 6 2.1 Executive Summary ....................................................................................................................................... 6 2.2 Operations ..................................................................................................................................................... 6 2.2.1 Objectives & indicators - risks & mitigations ....................................................................................... 6 2.2.2 Scientific priorities for 2020 ............................................................................................................... 14 A. Neurodegeneration and other neuroscience priorities .................................................................
    [Show full text]
  • Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk
    This PDF is available from The National Academies Press at http://www.nap.edu/catalog.php?record_id=18998 Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk ISBN Committee on Strategies for Responsible Sharing of Clinical Trial Data; 978-0-309-31629-3 Board on Health Sciences Policy; Institute of Medicine 280 pages 6 x 9 PAPERBACK (2015) Visit the National Academies Press online and register for... Instant access to free PDF downloads of titles from the NATIONAL ACADEMY OF SCIENCES NATIONAL ACADEMY OF ENGINEERING INSTITUTE OF MEDICINE NATIONAL RESEARCH COUNCIL 10% off print titles Custom notification of new releases in your field of interest Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Request reprint permission for this book Copyright © National Academy of Sciences. All rights reserved. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk Sharing Clinical Trial Data Maximizing Benefits, Minimizing Risk Committee on Strategies for Responsible Sharing of Clinical Trial Data Board on Health Sciences Policy PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright © National Academy of Sciences. All rights reserved. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.
    [Show full text]
  • Doctors, $$ and Drug Development: T H E R Ise of F Or-P Rofi T E X Perimental M Edicine
    Doctors, $$ and Drug Development: T h e R ise of F or-P rofi t E x perimental M edicine Pierre Azoulay Ariel Fishman M IT and N B E R C olumb ia U niv ersity S loan S chool of M anag ement G rad uate S chool of B usiness 5 0 M emorial D riv e, E 5 2 -5 5 5 3 0 2 2 B road w ay, U ris H all C amb rid g e, M A 0 2 1 4 2 N ew Y ork , N Y 1 0 0 2 7 S ep temb er 1 3 , 2 0 0 6 Abstract Over the past 15 years, academic medical centers have ceased to be the preferred locus of industry-sponsored clinical trial activity. Instead, clinical trials have increasing ly been con- ducted in private practices and for-profi t, dedicated study sites. On the demand side, the g reater availability of non-academic investig ators enabled pharmaceutical fi rms to better match physicians' sk ills w ith specifi c projects. On the supply side, the g row th of manag ed care health insurance has contributed to a rise in the number of physicians w ork ing in the for-profi t clinical trials industry. U sing a uniq ue panel dataset based on information about 9 7 ,2 2 5 clinical trial contracts g ranted betw een 19 9 1 and 2 0 0 3 , w e fi rst show that the proportion of academic in- vestig ators in a clinical trial correlates w ith project characteristics that plausibly prox y for the importance of k now ledg e-production activities.
    [Show full text]
  • Faqs on New Drugs and Clinical Trial Rules 2019
    Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on New Drugs and Clinical Trials Feedback/Suggestions, if any, in this regard, may be submitted to: Central Drugs Standard Control Organization Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India FDA Bhavan, ITO, Kotla Road, New Delhi -110002 Email: [email protected] Notice: The replies to the FAQs are aimed only for creating public awareness about regulation of New Drugs and Clinical Trials and are not meant to be used for legal or professional purposes. The readers are advised to refer to the statutory provisions of Drugs and Cosmetics Act & Rules and respective Guidelines / Clarifications issued by CDSCO from time to time for all their professional needs. FAQs on New Drugs and Clinical Trials 1. Whether the New Drugs and Clinical Trial Rules, 2019 (NDs & CTs Rules, 2019) is applicable only for New Drugs and Investigational New drugs for human use? Yes. Regulation for New drugs for veterinary use will continue to be as per Part XA of the Drugs and Cosmetics Rules, 1945. 2. What is a “new drug”? A new drug means; i. a drug, including active pharmaceutical ingredient or phytopharmaceutical drug, which has not been used in the country to any significant extent has not been approved as safe and efficacious by Central Licencing Authority (CLA) i.e. DCG(I) with respect to its claims; or ii. a drug approved by the CLA for certain claims and proposed to be marketed with modified or new claims including indication, route of administration, dosage and dosage form; or iii.
    [Show full text]
  • Scientific Report 2019
    2006 2007 2008 2009 2010 2011 2012 2013 2014 Tick tock toward 2025 toward tock Tick 2019 REPORT SCIENTIFIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Vall d'Hebron Institute of Oncology (VHIO) CELLEX CENTER C/Natzaret, 115 – 117 08035 Barcelona, Spain Tel. +34 93 254 34 50 www.vhio.net Direction: Amanda Wren Photography: Katherin Wermke Design: Parra estudio Vall d'Hebron Institute of Oncology (VHIO) | 2020 VHIO’s Scientific Report 2019: tick tock toward 2025 1 VHIO’s CELLEX CENTER: translation toward precision oncology 2 VHIO Scientific Report 2019 VHIO’s Scientific Report 2019: tick tock toward 2025 Index VHIO Scientific Report 2019 INTRODUCING VHIO 6 Foreword by VHIO’s Director 16 VHIO in 2019: Tick tock toward 2025 42 Scientific Productivity: research articles 43 Selection of some of the most relevant articles by VHIO researchers published in 2019 FROM THE PROGRAM DIRECTORS 52 Joaquín Arribas 54 Joan Seoane 56 Josep Tabernero PRECLINICAL & TRANSLATIONAL RESEARCH 64 Cellular Plasticity & Cancer Group 66 Chromatin Dynamics in Cancer Group 68 Experimental Therapeutics Group 70 Gene Expression & Cancer Group 72 Growth Factors Group 74 Mouse Models of Cancer Therapies Group 76 Stem Cells & Cancer Group 78 Tumor Biomarkers Group CLINICAL RESEARCH 82 Breast Cancer & Melanoma Group 84 Early Clinical Drug Development Group 86 Experimental Hematology Group 88 Gastrointestinal & Endocrine Tumors Group 90 Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group 92 Gynecological Malignancies Group 94 Hereditary Cancer
    [Show full text]
  • Synthesizing Existing Evidence to Design Future Trials: Survey of Methodologists in Europe
    Synthesizing existing evidence to design future trials: survey of methodologists in Europe Adriani Nikolakopoulou1, Sven Trelle1,2, Alex J Sutton3, Matthias Egger1, Georgia Salanti1* 1Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland 2Clinical Trials Unit, University of Bern, Bern, Switzerland 3Department of Health Sciences, University of Leicester, Leicester, UK * Corresponding author 1 Abstract Background: The potential of network meta-analysis to inform the design of future studies is largely underutilised. A suggested framework for efficiently planning clinical trials based on a network of interventions has been termed conditional trial design and consists of three parts. The first part pertains mainly to interpretation of meta-analysis and addresses whether the existing evidence answers the research question. The second part of the framework bears upon how best to use the existing evidence to answer the research question, and the third part addresses how to use the existing evidence to plan future research. Methods: We conducted an online survey among trial statisticians, methodologists and users of evidence synthesis research to capture opinions about all parts of the conditional trial design framework and the practices among clinical researchers. Results: In total, 76 contacted researchers completed the survey. We found that the level of acceptance of network meta-analysis is low to moderate. Three out of four survey participants were willing to consider using evidence synthesis to design a future clinical trial and around half of the participants would give priority to such a trial design. The median rating of the frequency of using it was 0.41 on a scale from 0, which stands for never, to 1, which stands for always.
    [Show full text]